How has chronic myelogenous leukemia (CML) treatment and care evolved? Dr. Michael Deininger, a leading expert, discusses ongoing research, treatment side effect management and the results of a 10-year study on survival rates and imatinib (Gleevec). Dr. Deininger goes on to explore the accessibility of certain medicines, the importance of molecular testing, and how clinical trials show doctors and patients what is possible for the future of treatment.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo